Asclera® (polidocanol) Injection

Distributed by Merz North America
Merz North America at 1-866-862-1211
FDA at 1-800-FDA-1088

Healthcare Professionals

Clinical Experience

Asclera® Injection was evaluated in a multicenter, randomized, double-blind, placebo and comparator-controlled trial (EASI-study) in patients with spider or reticular varicose veins. A total of 338 patients were treated with Asclera® [0.5% for spider veins (n=94), 1% for reticular veins (n=86), sodium tetradecyl sulfate (STS) 1% (n=105), or placebo (0.9% isotonic saline solution) (n= 53)] for either spider or reticular veins.

Patients received an intravenous injection in the first treatment session; repeat injections were given three and six weeks later if the previous injection was evaluated as unsuccessful (defined as 1, 2, or 3 on a 5-point scale).

Patients returned at 12 and 26 weeks after the last injection for final assessments. The primary effectiveness endpoint was improvement of veins judged by a blinded panel.

Treatment Success1

  • 95% of patients treated with Asclera® showed good or complete treatment success as rated by physicians
  • Asclera® treatment results were statistically significant when compared to placebo (p<0.0001) for the primary efficacy criterion “improvement of veins”


1 Treatment success was rated on a 5-point scale (1 = worse than before, 2 = same as before, 3 = moderate improvement, 4 = good improvement, 5 = complete treatment success) by a blinded panel.